Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Cumberland Pharmaceuticals (CPIX) over the last 2 years, with Mar 2011 value amounting to $78.5 million.

  • Cumberland Pharmaceuticals' Cash & Equivalents fell 12.99% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 12.99%. This contributed to the annual value of $18.0 million for FY2024, which is 1.95% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Cash & Equivalents of $15.2 million as of Q3 2025, which was down 5.54% from $16.1 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' Cash & Equivalents' 5-year high stood at $27.0 million during Q4 2021, with a 5-year trough of $15.1 million in Q1 2025.
  • Its 3-year average for Cash & Equivalents is $17.2 million, with a median of $17.5 million in 2024.
  • Data for Cumberland Pharmaceuticals' Revenue - Interest and Investment Income shows a peak YoY rose of 7.64% (in 2010) over the last 5 years.
  • Quarterly analysis of 3 years shows Cumberland Pharmaceuticals' Revenue - Interest and Investment Income stood at $72.3 million in 2009, then climbed by 7.64% to $77.8 million in 2010, then climbed by 6.42% to $78.5 million in 2011.
  • Its last three reported values are $15.2 million in Q3 2025, $16.1 million for Q2 2025, and $15.1 million during Q1 2025.